Topics:

Rhône-Poulenc Rorer Acquires Applied Immune Sciences

Rhône-Poulenc Rorer Acquires Applied Immune Sciences

COLLEGEVILLE, PA--Rhône-Poulenc Rorer Inc. and Applied Immune Sciences, Inc. (AIS) have entered into a definitive agreement and plan of merger providing for the acquisition by Rhône-Poulenc Rorer (through its subsidiary RPR Gencell) of AIS at a price of approximately $7.2 million.

AIS is a leader in cell therapy. At the heart of AIS' technology is a patented device, the AIS CELLector, that isolates specific populations of a patient's cells from blood, bone marrow, or tissue samples, The cells may then be activated and numerically expanded prior to reinfusion.

The AIS research facility in Santa Clara, Calif, will become the primary US operating headquarters for RPR Gencell with a focus on the development of ex vivo gene and cell therapy approaches, said Thierry Soursac, MD, PhD, senior vice president, RPR, and general manager, RPR Gencell.

 
Loading comments...
Please Wait 20 seconds or click here to close